Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates - PR Newswire
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates PR Newswire
Construction and validation of a clinical risk model based on machine learning for screening characteristic factors of lymphovascular space invasion in endometrial cancer - Nature.com
Construction and validation of a clinical risk model based on machine learning for screening characteristic factors of lymphovascular space invasion in endometrial cancer Nature.com
Deep learning to assess microsatellite instability directly from histopathological whole slide images in endometrial cancer | npj Digital Medicine - Nature.com
Deep learning to assess microsatellite instability directly from histopathological whole slide images in endometrial cancer | npj Digital Medicine Nature.com
Identification of Biomarkers for Endometrial Cancer Shows Promise for Faster and Less Invasive Diagnosis - The University of Arizona College of Medicine – Phoenix
Identification of Biomarkers for Endometrial Cancer Shows Promise for Faster and Less Invasive Diagnosis The University of Arizona College of Medicine – Phoenix
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer - GlobeNewswire
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous …